Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients with hematologic malignancies undergoing stem cell mobilization in association with chemotherapy, prior to autologous stem cell transplantation.~2. Prior Treatment:No parenteral cytotoxic chemotherapy within 2 weeks prior to initiation of chemo-mobilization therapy.~3. Performance Status: Karnofsky \> 70%~4. Age \>18~5. Life Expectancy \> 4 months~6. Bone Marrow: bone marrow biopsy and aspirate~7. Blood counts: The patient must have adequate bone marrow function, i.e. a total WBC of \> 2,000/ul, a Hgb of \> 7 g/dl, and a platelet count of \> 50,000/ul, unless this abnormality is believed to be due to the underlying disease.~8. Pulmonary function tests: DLCO \> 55% predicted.~9. Cardiac: Left ventricular ejection fraction of \> 40% by radionuclide scan or echocardiography.~10. Liver function tests (bilirubin, alkaline phosphatase, and SGOT/SGPT) \< 3 x normal (unless believed to be elevated due to disease).~11. Renal function (24 hour urine for creatinine clearance, if clinically indicated): The patient must have adequate renal function (creatinine clearance \>50 ml/min), except when renal insufficiency is felt related to the underlying malignancy.~12. No significant co-morbid medical or psychiatric illness that would significantly compromise the patient's clinical care and chances of survival in the transplant setting.~13. No significant established splenomegaly (i.e. spleen size \> 20 cm)~14. Informed written consent must be obtained. Patients must be able to give informed consent as a prerequisite to this procedure. The Informed Consent form will become part of his/her permanent record and a copy will be given to the patient.~Exclusion Criteria:~1. Patients with greater than three pre-transplant chemotherapy regimens and/or poor stem cell reserve as demonstrated by significant marrow hypocellularity (\<20%) will not be mobilized on the first phase regimen~2. Medical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapy.~3. Evidence on physical exam, LP, CT, or MRI scan of CNS involvement with malignancy.~4. Uncontrolled or severe cardiovascular disease, including recent (\< 6 months) myocardial infarction, congestive heart failure, angina (symptomatic despite optimal medical management), life-threatening dysrhythmia, or clinically significant obstructive/restrictive pulmonary disease.~5. Serology positive for HIV.~6. Positive pregnancy test or presence of lactation.~7. Uncontrolled active infection.~8. Documented hypersensitivity to any of the drugs used in the protocol.~9. No concomitant,ongoing malignancy that is life-threatening, based on PI's evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): All eligible patients will receive chemotherapy and one dose of Pegfilgrastim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues